\

Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Press Releases

Get News Alerts by Email

Jan 15, 2021

Cardiff Oncology Presents Data that Continues to Demonstrate the Clinical Benefit of Onvansertib in KRAS-Mutated mCRC and Initial Findings from its Expanded Access Program

- Of the 12 Phase 1b patients evaluable for efficacy as of the ASCO-GI data cut-off date (November 1, 2020), 5 (42%) achieved a partial response (PR) and 8 (67%) have shown a durable response ranging from 6.1 to 13.7 months
Dec 21, 2020

Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board
Dec 6, 2020

Cardiff Oncology Presents Data at ASH Demonstrating the Safety and Anti-Leukemic Activity of Onvansertib in Patients with Relapsed/Refractory AML
Nov 23, 2020

Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference
Nov 5, 2020

Cardiff Oncology Announces Third Quarter 2020 Results and Highlights

Show per page